T cell response against SARS-CoV-2 persists after one year in patients surviving severe COVID-19.

ABSTRACT:

Background

In critically ill COVID-19 patients, the initial response to SARS-CoV-2 infection is characterized by major immune dysfunctions. The capacity of these severe patients to mount a robust and persistent SARS-CoV-2 specific T cell response despite the presence of severe immune alterations during the ICU stay is unknown.

Methods

Critically ill COVID-19 patients were sampled five times during the ICU stay and 9 and 13 months afterwards. Immune monitoring included counts of lymphocyte subpopulations, HLA-DR expression on monocytes, plasma IL-6 and IL-10 concentrations, anti-SARS-CoV-2 IgG levels and T cell proliferation in response to three SARS-CoV-2 antigens.

Findings

Despite the presence of major lymphopenia and decreased monocyte HLA-DR expression during the I

SUBMITTER: Venet F 

PROVIDER: S-EPMC8957405 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature